Overweight

Individuals with obesity have long felt stigmatized and shamed in health care settings.

Adults with obesity for 20 years or more who received tirzepatide had a similar reduction in body weight and waist circumference as adults with shorter obesity duration, according to a post hoc analysis of four SURMOUNT trials.

Girls with obesity or overweight were more likely to see their general practitioner for a musculoskeletal consultation, according to a study published in Archives of Disease in Childhood.

An online obesity treatment and maintenance program resulted in significant weight loss among primary care patients, according to findings from a randomized study published in JAMA Internal Medicine.

Novo Nordisk and the FDA announced approval of a new indication for semaglutide 2.4 mg for reduction of risk for major adverse cardiovascular events in adults with overweight or obesity and established CVD.

Deteriorating quality of life for women with breast cancer was associated with many common modifiable psychosocial and lifestyle-related factors, according to an analysis published in JAMA Network Open.

Men who had a lower birth weight followed by overweight during young adulthood have a greatly increased risk for developing type 2 diabetes vs. those with normal weight at those times, according to study results published in Diabetologia.

An increase in symptoms of depression was linked to a small increase in weight among adults with overweight or obesity, according to a recent study in PLOS One.

As the first point of contact for many patients, it is important for primary care physicians to have strategies that will help treat and manage overweight and obesity, according to experts.

PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.